Bringing the fundamentals into focus…
Back to Castle Biosciences, Inc.
How Castle Biosciences, Inc. stacks up
CSTL · against 1,216 other Healthcare companies
Growth
57/ 100
Above the middle of the pack.
Ranked #518 of 1,217 · scores higher than 57% of peers
Bars: peers in each 10-point band of the growth score122 peers with a growth score of 50–59, including CSTL · Click a bar to see the companies
Why growth scores 57?
Weighted metrics compared with all Healthcare companies.A mix: stronger 3-year revenue growth, but weaker earnings per share growth than most Healthcare peers.
- The loss per share widened. Earnings per share growth: — vs peer median 9.8%
- Revenue growth is close to the peer norm. Revenue growth: 3.2% vs peer median 6.1%
- faster revenue growth over three years: stronger than 87% of peers. 3-year revenue growth: 28.7% vs peer median 5.8%
Metric by metric
Position: dot = CSTL, ranked from the worst peer (left) to the best (right); tick = middle, shaded = middle half of peers.| Metric | CSTL | Peer median | Better than | Position among peers | Weight |
|---|---|---|---|---|---|
| Revenue growthHigher is better · 1,243 reported | 3.2% | 6.1% | 40% | 33% | |
| Earnings per share growthHigher is better · 682 reported | Not reported | 9.7% | — | — | 33% |
| 3-year revenue growthHigher is better · 1,192 reported | 28.7% | 5.8% | 87% | 33% |
A metric that is not reported is left out of the score; the other weights are rescaled.
Ranking by growth score
Top 5 and the companies ranked around CSTL| Rank | Company | Market cap | Growth | Overall |
|---|---|---|---|---|
| 1 | 3.1B EUR (≈$3.4B) | 100 | 100 | |
| 1 | 464M USD | 100 | 53 | |
| 3 | 8.9B HKD (≈$1.1B) | 99 | 61 | |
| 3 | 1.8B HKD (≈$224M) | 99 | 59 | |
| 3 | 7.2B TWD (≈$224M) | 99 | 41 | |
| 518 | 37.3B JPY (≈$254M) | 57 | 66 | |
| 518 | 6.7B CNY (≈$941M) | 57 | 52 | |
| 518 | 7.2B USD | 57 | 43 | |
| 518 | 11.6B USD | 57 | 56 | |
| 518 | 1.1B USD | 57 | 43 | |
| 518 | 1.5B EUR (≈$1.7B) | 57 | 60 | |
| 518 | 12.6B EUR (≈$13.9B) | 57 | 73 | |
| 518 | 18.29T IDR (≈$1.1B) | 57 | 79 | |
| 518 | 302.7B USD | 57 | 63 |
Scores are sector-relative percentiles from the latest snapshot, always calculated against the whole sector: narrowing the comparison group changes who you compare with, not the scores. Missing metrics are left out and the remaining weights rescaled. How we score